Center of Experimental and Molecular Medicine Center of Tropical Medicine and Travel Medicine, Division of Infectious Diseases Centre des Recherches Médicales de Lambaréné, Gabon.
Department of Immunopathology, Sanquin Blood Supply Division of Research, Joint Academic Medical Center-Sanquin Landsteiner Laboratory, Amsterdam, The Netherlands.
J Infect Dis. 2015 Aug 1;212(3):474-83. doi: 10.1093/infdis/jiv074. Epub 2015 Feb 5.
Human immunodeficiency virus (HIV)-induced complement activation may play a role in chronic immune activation in patients with HIV infection and influence the complement system during acute illness. We determined the impact of HIV infection on the complement system in patients with asymptomatic HIV infection and HIV-infected patients with sepsis or malaria.
We performed a prospective observational study of 268 subjects with or without HIV infection who were asymptomatic, were septic, or had malaria. We measured complement activation products (C3bc and C4bc) and native complement proteins (C3 and C4). levels of mannose-binding lectin and C1q-C4 were measured to examine activation of the lectin and classical pathways, respectively.
Asymptomatic HIV infection was associated with increased C4 activation, especially in patients with high HIV loads, and was accompanied by elevated C1q-C4 levels. Similarly, sepsis and malaria resulted in increased C4 activation and elevated C1q-C4 concentrations. HIV coinfection enhanced C4 activation and consumption in patients with sepsis; this effect was not detected in patients with malaria. Mannose-binding lectin deficiency (defined as a mannose-binding lectin level of <500 ng/mL) did not influence complement activation in any group.
HIV activates the complement system, predominantly via the classical pathway, and causes increased C4 activation and consumption during sepsis. HIV-induced complement activation may contribute to tissue injury during chronic infection and acute intercurrent bacterial infections.
人类免疫缺陷病毒(HIV)诱导的补体激活可能在 HIV 感染患者的慢性免疫激活中发挥作用,并影响急性疾病期间的补体系统。我们确定了 HIV 感染对无症状 HIV 感染和 HIV 感染合并脓毒症或疟疾患者补体系统的影响。
我们对 268 例无症状、脓毒症或疟疾的 HIV 感染或未感染患者进行了前瞻性观察性研究。我们测量了补体激活产物(C3bc 和 C4bc)和天然补体蛋白(C3 和 C4)。测量甘露聚糖结合凝集素和 C1q-C4 的水平,以分别检查凝集素和经典途径的激活。
无症状 HIV 感染与 C4 激活增加有关,尤其是在 HIV 载量高的患者中,并伴有 C1q-C4 水平升高。类似地,脓毒症和疟疾导致 C4 激活增加和 C1q-C4 浓度升高。HIV 合并感染增强了脓毒症患者的 C4 激活和消耗;在疟疾患者中未检测到这种作用。甘露聚糖结合凝集素缺乏症(定义为甘露聚糖结合凝集素水平<500ng/mL)并未影响任何组的补体激活。
HIV 激活补体系统,主要通过经典途径,并在脓毒症期间导致 C4 激活和消耗增加。HIV 诱导的补体激活可能导致慢性感染和急性并发细菌感染期间的组织损伤。